Hip Fracture Surgery in Elderly Patients

NCT ID: NCT01199276

Last Updated: 2015-07-27

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

256 participants

Study Classification

INTERVENTIONAL

Study Start Date

2010-09-30

Study Completion Date

2014-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The objective of this study is to evaluate the incidence of Post-Operative Delirium (POD), diagnosed with the Confusion Assessment Method (CAM), in elderly patients undergoing hip fracture surgery under general anaesthesia with xenon or sevoflurane, for a period of four days post-surgery.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Delirium

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Xenon

60%(1MAC)in oxygen (FiO2 = 0.35-0.45)

Group Type EXPERIMENTAL

Xenon

Intervention Type DRUG

Group A: xenon 60% (55%-65%)(1 MAC) in oxygen (FiO2 = 0.35-0.45)

Sevoflurane

1.1-1.4% (1 MAC) in oxygen (FiO2 = 0.35-0.45) and medical air

Group Type ACTIVE_COMPARATOR

Sevoflurane

Intervention Type DRUG

Group B: sevoflurane 1.1-1.4%(1 MAC) in oxygen (FiO2 = 0.35-0.45) and Medical air

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Xenon

Group A: xenon 60% (55%-65%)(1 MAC) in oxygen (FiO2 = 0.35-0.45)

Intervention Type DRUG

Sevoflurane

Group B: sevoflurane 1.1-1.4%(1 MAC) in oxygen (FiO2 = 0.35-0.45) and Medical air

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

LENOXe

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Elderly patient (≥ 75 years)
* Patient with planned hip fracture surgery within 48 hours after the hip fracture
* Patient willing and able to complete the requirements of this study including the signature of the written informed consent

Exclusion Criteria

* Patient suffering from multiple fractures, pelvic fractures proximal, pathological fractures, femur fractures (i.e., fractures of the middle or distal femur)
* Disabling neuropsychiatric disorders (severe dementia, Alzheimer's disease, schizophrenia, depression)
* Brain trauma within 12 months prior to selection, history of stroke with residuals
* Patient suffering from delirium (CAM diagnosis) at selection
* Patient who cannot complete the pre-operative mental tests (CAM and/or MMSE) of this clinical trial
* Patient with Mini-Mental State Examination (MMSE) score \< 24 at selection
* Patient known to susceptible to malignant hyperthermia
* Patient with elevated intra-cranial pressure
* Patient with a risk of high oxygen demand
* Patient with recent or ongoing myocardial infarction / damage
* Patient with severe cardiac failure, or patient with severe impaired left ventricular systolic function
* Patient with known severe lung and/or airway disease, or severe chronic respiratory insufficiency, or a sustained homecare oxygen therapy
* Contra-indication (serious illness or medical conditions) for general anaesthesia
* Known allergy or hypersensitivity to any drugs administered during this clinical trial
* Previous participation in this clinical trial
* Participation in another clinical trial within 4 weeks prior to selection
* History of alcohol or drug abuse or psychiatric disorders which would impair the understanding of the necessary information or render medically or legally unable to give written informed consent
Minimum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

OptumInsight

UNKNOWN

Sponsor Role collaborator

Air Liquide Santé International

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Mark COBURN, MD

Role: STUDY_CHAIR

University Hospital Aachen - Germany

Robert SANDERS, MD

Role: STUDY_CHAIR

Imperial College London - UK

Rolf ROSSAINT, MD

Role: STUDY_CHAIR

University Hospital Aachen - Germany

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

UZ Leuven

Leuven, , Belgium

Site Status

Centre Hospitalier Universitaire de Grenoble

La Tronche, , France

Site Status

Centre Hospitalier Régional Universitaire de Montpellier

Montpellier, , France

Site Status

Groupe Hospitalier La Pitié-Salpêtriere

Paris, , France

Site Status

Groupe Hospitalier COCHIN

Paris, , France

Site Status

CHU Pontchaillou - Université de Rennes 1

Rennes, , France

Site Status

Centre Hospitalier Universitaire de Toulouse

Toulouse, , France

Site Status

University Hospital Aachen

Aachen, , Germany

Site Status

. Klinik für Anästhesiologie - Universitätsklinikum Düsseldorf

Düsseldorf, , Germany

Site Status

Klinikum Mutterhaus Der Borromaerinnen

Trier, , Germany

Site Status

IRCCS Rizzoli Orthopaedic Institute

Bologna, , Italy

Site Status

Hospital Clinico Universitario de Valencia

Valencia, , Spain

Site Status

Imperial College NHS Trust

London, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Belgium France Germany Italy Spain United Kingdom

References

Explore related publications, articles, or registry entries linked to this study.

Coburn M, Sanders RD, Maze M, Nguyen-Pascal ML, Rex S, Garrigues B, Carbonell JA, Garcia-Perez ML, Stevanovic A, Kienbaum P, Neukirchen M, Schaefer MS, Borghi B, van Oven H, Tognu A, Al Tmimi L, Eyrolle L, Langeron O, Capdevila X, Arnold GM, Schaller M, Rossaint R; HIPELD Study Investigators. The hip fracture surgery in elderly patients (HIPELD) study to evaluate xenon anaesthesia for the prevention of postoperative delirium: a multicentre, randomized clinical trial. Br J Anaesth. 2018 Jan;120(1):127-137. doi: 10.1016/j.bja.2017.11.015. Epub 2017 Nov 21.

Reference Type DERIVED
PMID: 29397119 (View on PubMed)

Coburn M, Sanders RD, Maze M, Rossaint R; HIPELD Investigators. The Hip Fracture Surgery in Elderly Patients (HIPELD) study: protocol for a randomized, multicenter controlled trial evaluating the effect of xenon on postoperative delirium in older patients undergoing hip fracture surgery. Trials. 2012 Sep 27;13:180. doi: 10.1186/1745-6215-13-180.

Reference Type DERIVED
PMID: 23016882 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

ALMED-08-C2-020

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.